Last updated on August 2020

Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)


Brief description of study

This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo in subjects with MCL.

Clinical Study Identifier: NCT03112174

Find a site near you

Start Over

City of Hope

Duarte, CA United States
  Connect »

Orlando Health Inc.

Orlando, FL United States
  Connect »

Ingalls Memorial Hospital

Harvey, IL United States
  Connect »

Norton Cancer Institute

Louisville, KY United States
  Connect »

Stony Brook University

New York, NY United States
  Connect »

Levine Cancer Institute

Charlotte, NC United States
  Connect »

Tennessee Oncology

Chattanooga, TN United States
  Connect »

Swedish Cancer Institute

Seattle, WA United States
  Connect »

Icon Cancer Care

Auchenflower, Australia
  Connect »

Austin Health

Heidelberg, Australia
  Connect »

AZ Groeninge

Kortrijk, Belgium
  Connect »

FN Olomouc

Olomouc, Czechia
  Connect »

FN Ostrava

Ostrava-Poruba, Czechia
  Connect »

Centre Hospitalier Lyon Sud

Pierre Benite cedex, France
  Connect »

CHU de Tours

Tours Cedex 01, France
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Spaarne Gasthuis

Hoofddorp, Netherlands
  Connect »

Erasmus MC

Rotterdam, Netherlands
  Connect »

Franciscus Vlietland

Schiedam, Netherlands
  Connect »

Barts Health NHS Trust

London, United Kingdom
  Connect »

The Churchill Hospital

Oxford, United Kingdom
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.